Scarica l'app Stockscreener
6.80
6.25%
0.40
Pre-mercato:
6.56
-0.24
-3.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
Bioxcel Therapeutics 2025 Q2 Earnings Widened Net Loss Amid Revenue Drop - AInvest
BioXcel Therapeutics Reports Q2 2025 Financial Results - TipRanks
BioXcel Therapeutics Surges 6.25% on $230M Volume Ranking 441st as Clinical Pipeline and Patent Expansions Bolster Investor Confidence - AInvest
BIOXCEL THERAPEUTICS Earnings Results: $BTAI Reports Quarterly Earnings - Quiver Quantitative
BioXcel Therapeutics (BTAI): Assessing the Impact of SERENITY Trial Outcomes on At-Home Agitation Market Potential - AInvest
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
BioXcel at Canaccord Genuity: Strategic Insights on Phase 3 Trials By Investing.com - Investing.com Canada
BioXcel Therapeutics (BTAI) Q2 Financial Report: Wider Loss, Revenue Decrease, and Upcoming Business Updates - AInvest
BioXcel Therapeutics (BTAI) Stock Is Extremely Volatile Today: What's Going On? - Benzinga
BioXcel Therapeutics Stock Soars Amid Positive Clinical and Patent Developments - StocksToTrade
BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
BioXcel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioXcel Therapeutics, Inc. SEC 10-Q Report - TradingView
Bioxcel Therapeutics Plunges 12.03% on Q2 Loss, Revenue Drop - AInvest
BioXcel Therapeutics Q2 Earnings Miss Estimates, Revenue Down 89.1% Y/Y - AInvest
BioXcel Therapeutics Inc Reports Q2 2025 Earnings: EPS of -$1.56, Revenue Misses Estimates at $120K - GuruFocus
BioXcel Therapeutics Reports Q2 2025 Financials, Topline Data Expected in August. - AInvest
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - TradingView
BioXcel Therapeutics' Q2 2025 Earnings Disappointment: A Test of Biotech Resilience - AInvest
BioXcel Therapeutics Reports Q2 Earnings, SERENITY At-Home Trial Topline Expected in August. - AInvest
Press Release: BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - 富途牛牛
Bioxcel Therapeutics Surges 58.42% on $230M Volume Ranks 452nd in Market Activity as BXCL501 Trial Progress Fuels Investor Optimism - AInvest
BioXcel Therapeutics to Participate in Canaccord Genuity Growth Conference - AInvest
BioXcel Therapeutics Raises $30.4M, Meets Financing Covenant - TipRanks
Bioxcel Therapeutics (BTAI.O) Surges Over 21%: A Deep Dive Into the Drivers Behind the Unusual Move - AInvest
BioXcel’s BXCL501 Study: A Potential Game-Changer for Psychomotor Agitation Treatment - TipRanks
BioXcel Highlights BXCL501’s Market Potential for Agitation - TipRanks
BioXcel Therapeutics CEO to speak at Canaccord Genuity Growth Conference. - AInvest
BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
BioXcel CEO Reveals Next-Gen AI Neuroscience Innovations at Major Growth ConferenceStrategic Updates Coming - Stock Titan
Bioxcel Therapeutics (BTAI.O) Surges 12.6% Without Fundamental Catalyst: A Technical and Order-Flow Deep Dive - AInvest
Bioxcel Therapeutics (BTAI) Surges 28% on Intraday Rally: What’s Fueling the Momentum? - AInvest
BTAI Surges 27% on Unprecedented Momentum: What’s Fueling the Biotech Breakout? - AInvest
Top Penny Stocks to Watch: Ainos, SG Blocks, and BioXcel Therapeutics - AInvest
BioXcel Therapeutics Sees Stock Surge Amid Positive Phase 3 Results in At-Home Trial - timothysykes.com
Best Penny Stocks To ConsiderAugust 5th - MarketBeat
BioXcel Therapeutics Stock (BTAI) Opinions on Phase 3 SERENITY Trial Completion - Quiver Quantitative
BioXcel Therapeutics Anticipates Major Breakthrough with Completion of SERENITY At-Home Trial - StocksToTrade
Bioxcel Therapeutics (BTAI.O) Surges 17.17%—What’s Driving the Intraday Move? - AInvest
Bioxcel Therapeutics shares rise 4.38% premarket after publication in Frontiers in Pharmacology. - AInvest
Bioxcel Therapeutics Soars 11.11% on Positive Drug Study - AInvest
BioXcel Study Highlights Dexmedetomidine’s Potential Benefits - TipRanks
Bioxcel Therapeutics shares rise 11.78% premarket after positive study results for BXCL501 in chronic psychiatric disorders. - AInvest
BioXcel study shows dexmedetomidine reduces stress behaviors By Investing.com - Investing.com Nigeria
BioXcel study shows dexmedetomidine reduces stress behaviors - Investing.com India
BTAI files 424B5 to sell up to $3.5M in stock via ATM program - Stock Titan
BioXcel Therapeutics Announces Publication in Frontiers in - GlobeNewswire
Breakthrough Study: BioXcel's BXCL501 Could Transform Treatment of Chronic Psychiatric Disorders - Stock Titan
Mizuho Securities Maintains Hold Rating for Bioxcel Therapeutics with $2.00 Price Target - AInvest
Bioxcel Therapeutics Soars 27% Intraday: What's Fueling This Biotech Surge? - AInvest
BioXcel’s Clinical Breakthrough Marks Market Anticipation - timothysykes.com
Bioxcel Therapeutics (BTAI.O) Surges 13.39%: What’s Behind the Unusual Intraday Move? - AInvest
3 Penny Stocks to Watch: Tenon Medical, BioXcel Therapeutics, I-Mab - AInvest
Why Did Bioxcel Therapeutics Drop 6.69%? - AInvest
Bioxcel Therapeutics: Buy Rating Driven by SERENITY Trial Milestone and Strategic Expansion. - AInvest
BioXcel Therapeutics, Inc.Common Stock (Nasdaq:BTAI) Stock Quote - FinancialContent
Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright reiterates Buy rating on BioXcel Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy rating on BioXcel Therapeutics stock - Investing.com
Bioxcel Therapeutics (BTAI) Surges 29.9% on Phase 3 Trial Completion — What’s Next for the Biotech Breakout? - AInvest
BioXcel Therapeutics Stock Unveiled: Rollercoaster Insights - StocksToTrade
BioXcel Therapeutics Surges: What’s Behind the Move? - timothysykes.com
Bioxcel Therapeutics: Buy Rating Driven by SERENITY Trial Milestone and Strategic Expansion - TipRanks
What makes BioXcel Therapeutics Inc. stock price move sharplyBuild wealth faster with consistent growth stocks - Jammu Links News
BioXcel Therapeutics Inc. Stock Analysis and ForecastInvest confidently with real-time market updates - Jammu Links News
What are BioXcel Therapeutics Inc. company’s key revenue driversGet professional guidance for market timing - Jammu Links News
Why is BioXcel Therapeutics Inc. stock attracting strong analyst attentionInvest smarter with data-backed insights - Jammu Links News
Does BioXcel Therapeutics Inc. stock perform well during market downturnsOutstanding investment returns - Jammu Links News
Is it the right time to buy BioXcel Therapeutics Inc. stockInvest confidently with real-time market updates - Jammu Links News
What is the dividend policy of BioXcel Therapeutics Inc. stockGet timely alerts on market opportunities - Jammu Links News
How does BioXcel Therapeutics Inc. generate profit in a changing economyLightning-fast capital gains - Jammu Links News
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):